The first stop for professional medicines advice

Biosimilars Updates

Regularly updated biosimilars material, in addition to our annual outputs. Includes specific information on ranibizumab for ocular use.

Understand the area

Understanding biological and biosimilar medicines
Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
Training and Development materials29 June 2022

Ranibizumab for ocular use

Resources to specifically support the introduction of ranibizumab biosimilar for ocular use.

Preparing to use ranibizumab biosimilar
Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Ranibizumab29 June 2022
Good governance when implementing ranibizumab biosimilar
Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance.
Ranibizumab29 June 2022
The licence and supporting evidence for ranibizumab biosimilar
A licensed ranibizumab biosimilar is available from Teva: Ongavia. Learn about the licensed indications and supporting evidence.
Ranibizumab29 June 2022
Search Ranibizumab for ocular use

All our resources

All our resources on biosimilar medicines

Preparing to use ustekinumab biosimilar
16 July 2024
Choosing between available adalimumab products
Understand the adalimumab products that are available on contract to the NHS. Choose between them appropriately for organisations or individuals.
Biosimilars22 February 2023
Preparing to use ranibizumab biosimilar
Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Ranibizumab29 June 2022
Good governance when implementing ranibizumab biosimilar
Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance.
Ranibizumab29 June 2022
The licence and supporting evidence for ranibizumab biosimilar
A licensed ranibizumab biosimilar is available from Teva: Ongavia. Learn about the licensed indications and supporting evidence.
Ranibizumab29 June 2022
Understanding biological and biosimilar medicines
Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
Training and Development materials29 June 2022
National Homecare Medicines Committee (NHMC) Homecare Risk Assessment
To support organisations in establishing a robust risk assessment process for new homecare medicines services the NHMC has developed a tool for local use.  …
NHS England commissioned new medicines10 December 2019
National Homecare Medicines Committee (NHMC) Proposal for the funding of Pharmacy Homecare Teams
NHMC submitted a proposal for the funding of Trust Pharmacy Homecare Teams to NHS England and NHS Clinical Commissioning for consideration. The NHMC hopes that…
NHS England commissioned new medicines4 May 2018
NHMC Good Practice Principles for the Provision of Manufacturer Funded Homecare Services
These Good Practice Principles set out the National Homecare Medicines Committee’s (NHMC) expectations of Manufacturers offering Manufacturer Funded Homecare Medicine Services in relation to the…
NHS England commissioned new medicines5 March 2018
Guidance Handling of Monoclonal Antibody (mAb) and Products (Yellow Cover)
Variation in practice underlined the need for an evidence-based guideline for handling mAbs that was suited to all those providing care to NHS patients.
Regulatory16 December 2016
Search All our resources